SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-028106
Filing Date
2024-05-30
Accepted
2024-05-30 16:05:20
Documents
15
Period of Report
2024-05-30
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20030279-8k.htm   iXBRL 8-K 33410
2 EXHIBIT 99.1 ef20030279_ex99-1.htm EX-99.1 9221
6 logo.jpg GRAPHIC 4217
  Complete submission text file 0001140361-24-028106.txt   190834

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20240530.xsd EX-101.SCH 3907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20240530_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20240530_pre.xml EX-101.PRE 16072
19 EXTRACTED XBRL INSTANCE DOCUMENT ef20030279-8k_htm.xml XML 4205
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 241005171
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)